Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition

BACKGROUND: ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments and most of them eventually relap...

Descripción completa

Detalles Bibliográficos
Autores principales: Caffarel, María M, Andradas, Clara, Mira, Emilia, Pérez-Gómez, Eduardo, Cerutti, Camilla, Moreno-Bueno, Gema, Flores, Juana M, García-Real, Isabel, Palacios, José, Mañes, Santos, Guzmán, Manuel, Sánchez, Cristina
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917429/
https://www.ncbi.nlm.nih.gov/pubmed/20649976
http://dx.doi.org/10.1186/1476-4598-9-196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917429/
https://www.ncbi.nlm.nih.gov/pubmed/20649976
http://dx.doi.org/10.1186/1476-4598-9-196

Ejemplares similares